< Articles
Artificial Intelligence in Drug Discovery and Its Implications on Patents
AI is disrupting drug discovery—are patents ready to keep up?
Artificial intelligence (AI) is redefining how new drugs are discovered—making the process faster, smarter, and more precise than ever before. From identifying targets to designing first-in-class molecules, AI is radically shortening timelines and opening up new frontiers in pharmaceutical innovation.
However, these breakthroughs raise tough questions for the patent system:
- Who should be considered the inventor when AI contributes to drug design?
- Is our definition of “non-obvious” still relevant in the era of generative AI (GenAI)?
- Is computer-generated data enough to support claims that a treatment is effective?
In this expert report, we unpack these questions and explore the growing legal and evidentiary challenges shaping the future of pharmaceutical patents.
Download the full report to explore AI’s impact on the future of pharmaceutical patents.
The article referred to was published in the SAL Practitioner on 16 July 2025 on Journals Online. The original publication can be found here. © 2025 Contributor(s) and Singapore Academy of Law; no part of the article may be reproduced without permission from the copyright holders.
